Epidemiology and drug allergy results in children investigated in allergy unit of a tertiary-care paediatric hospital setting.


Journal

Italian journal of pediatrics
ISSN: 1824-7288
Titre abrégé: Ital J Pediatr
Pays: England
ID NLM: 101510759

Informations de publication

Date de publication:
10 Jan 2020
Historique:
received: 28 05 2019
accepted: 21 11 2019
entrez: 12 1 2020
pubmed: 12 1 2020
medline: 13 11 2020
Statut: epublish

Résumé

Drug Hypersensitivity Reactions (DHRs) are considered adverse effects of medications that resemble allergy symptoms. The reported positive clinical history of pediatric drug reactions is about 10%, however, after allergy investigations, only a small percent is confirmed as hypersensitivity. The aim of this study was to analyze the clinical history, allergy work-up results and sensitization profile of children and adolescents referred to our Allergy Unit for suspected DHRs. The study evaluated data related to a group of children with a positive history of drug reactions during a two-year period. The allergy work-up consisted of in vivo and in vitro tests, in accordance with the recommendations of the ENDA/EAACI guidelines. Data from a group of 637 patients [348 M (54.6%); 289 F (45.4%)] were retrospectively analyzed. Beta lactams (BLs) were the most common drugs involved in the reported clinical history, followed by non-steroidal anti-inflammatory drugs (NSAIDs). Severe cutaneous adverse reactions (SCARs) were most frequently observed during BL treatment. The confirmation of BL hypersensitivity was higher for immediate reactions (IRs) [9.4%; 5.1% through positive skin tests (STs) and 5.5% through drug provocation test (DPT)] compared to non-immediate reactions (non-IRs) (8.1%; 2.2% through STs and 6.2% through DPT). A higher number of positive results was obtained for BLs and macrolides when the tests were performed within 12 months after the index reaction (p < 0.05). During DPTs with amoxicillin-clavulanic acid, four hypersensitivity reactions (including one anaphylaxis) occurred despite negative STs. Our data demonstrated that only 9.1% of patients resulted in being positive to allergy tests which is in line with the data in literature. An allergy work-up is mandatory for excluding suspected hypersensitivity.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Drug Hypersensitivity Reactions (DHRs) are considered adverse effects of medications that resemble allergy symptoms. The reported positive clinical history of pediatric drug reactions is about 10%, however, after allergy investigations, only a small percent is confirmed as hypersensitivity. The aim of this study was to analyze the clinical history, allergy work-up results and sensitization profile of children and adolescents referred to our Allergy Unit for suspected DHRs.
METHODS METHODS
The study evaluated data related to a group of children with a positive history of drug reactions during a two-year period. The allergy work-up consisted of in vivo and in vitro tests, in accordance with the recommendations of the ENDA/EAACI guidelines.
RESULTS RESULTS
Data from a group of 637 patients [348 M (54.6%); 289 F (45.4%)] were retrospectively analyzed. Beta lactams (BLs) were the most common drugs involved in the reported clinical history, followed by non-steroidal anti-inflammatory drugs (NSAIDs). Severe cutaneous adverse reactions (SCARs) were most frequently observed during BL treatment. The confirmation of BL hypersensitivity was higher for immediate reactions (IRs) [9.4%; 5.1% through positive skin tests (STs) and 5.5% through drug provocation test (DPT)] compared to non-immediate reactions (non-IRs) (8.1%; 2.2% through STs and 6.2% through DPT). A higher number of positive results was obtained for BLs and macrolides when the tests were performed within 12 months after the index reaction (p < 0.05). During DPTs with amoxicillin-clavulanic acid, four hypersensitivity reactions (including one anaphylaxis) occurred despite negative STs.
CONCLUSION CONCLUSIONS
Our data demonstrated that only 9.1% of patients resulted in being positive to allergy tests which is in line with the data in literature. An allergy work-up is mandatory for excluding suspected hypersensitivity.

Identifiants

pubmed: 31924232
doi: 10.1186/s13052-019-0753-4
pii: 10.1186/s13052-019-0753-4
pmc: PMC6954623
doi:

Substances chimiques

Immunoglobulin E 37341-29-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5

Références

J Dermatol. 2013 Jul;40(7):522-7
pubmed: 23682746
Ann Allergy Asthma Immunol. 2017 Oct;119(4):362-373.e2
pubmed: 28779998
Pediatr Allergy Immunol. 2008 Nov;19(7):634-8
pubmed: 18221471
Pediatr Allergy Immunol. 2018 Feb;29(1):84-89
pubmed: 29047169
Pediatr Allergy Immunol. 2011 Jun;22(4):411-8
pubmed: 21535179
Allergy. 2009 Jun;64(6):962-3
pubmed: 19222423
Pediatr Allergy Immunol. 2015 Feb;26(1):80-2
pubmed: 25469811
Eur J Clin Pharmacol. 2013 Mar;69(3):673-81
pubmed: 22915040
Expert Rev Clin Pharmacol. 2016 Oct;9(10):1341-1349
pubmed: 27420754
J Investig Allergol Clin Immunol. 2015;25(2):128-32
pubmed: 25997306
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):825
pubmed: 25439388
Allergy. 2016 Jul;71(7):1048-56
pubmed: 26841325
Clin Infect Dis. 2014 May;58(10):1377-85
pubmed: 24599767
Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):121-6
pubmed: 24674687
Pediatr Allergy Immunol. 2014 Feb;25(1):80-7
pubmed: 24329898
Clin Transl Allergy. 2015 Sep 03;5:31
pubmed: 26339470
Allergy. 2016 Feb;71(2):149-61
pubmed: 26416157
Curr Opin Allergy Clin Immunol. 2012 Aug;12(4):369-75
pubmed: 22729028
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1217-1223
pubmed: 28988784
Pediatr Allergy Immunol. 2013 Mar;24(2):160-7
pubmed: 23373964
Pediatr Allergy Immunol. 2016 Aug;27(5):533-8
pubmed: 26999792
J Allergy Clin Immunol. 2011 Jan;127(1):218-22
pubmed: 21035175
Clin Exp Allergy. 2008 Jan;38(1):191-8
pubmed: 18028465
J Allergy Clin Immunol Pract. 2014 Jul-Aug;2(4):414-20
pubmed: 25017529
Pediatr Allergy Immunol. 2010 Nov;21(7):1043-51
pubmed: 20536783
Clin Exp Allergy. 2012 Jan;42(1):123-30
pubmed: 22092779
J Allergy Clin Immunol Pract. 2015 May-Jun;3(3):375-80.e1
pubmed: 25609343
Allergy. 2014 Apr;69(4):420-37
pubmed: 24697291

Auteurs

A Piccorossi (A)

Department of Pediatrics, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.

G Liccioli (G)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy. giulialiccioli@gmail.com.

S Barni (S)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy.

L Sarti (L)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy.

M Giovannini (M)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy.

A Verrotti (A)

Department of Pediatrics, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy.

E Novembre (E)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy.

F Mori (F)

Allergy Unit, Anna Meyer Children's Hospital, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH